Literature DB >> 29552661

SWOG study shows significant long-term overall survival for advanced gastrointestinal stromal tumor patients with imatinib treatment.

Marcel Trautmann1, Sebastian Huss1, Wolfgang Hartmann1, Eva Wardelmann1.   

Abstract

Entities:  

Year:  2018        PMID： 29552661      PMCID： PMC5847908          DOI： 10.21037/tgh.2018.01.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  21 in total

1.  Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.

Authors:  Florian Haller; Evgeny A Moskalev; Fabio R Faucz; Sarah Barthelmeß; Stefan Wiemann; Matthias Bieg; Guillaume Assie; Jerome Bertherat; Inga-Marie Schaefer; Claudia Otto; Eleanor Rattenberry; Eamonn R Maher; Philipp Ströbel; Martin Werner; J Aidan Carney; Arndt Hartmann; Constantine A Stratakis; Abbas Agaimy
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

Review 2.  Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.

Authors:  Sebastian Huss; Helen Pasternack; Michaela Angelika Ihle; Sabine Merkelbach-Bruse; Birthe Heitkötter; Wolfgang Hartmann; Marcel Trautmann; Heidrun Gevensleben; Reinhard Büttner; Hans-Ulrich Schildhaus; Eva Wardelmann
Journal:  Hum Pathol       Date:  2017-02-01       Impact factor: 3.466

3.  Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST).

Authors:  Ronald P Dematteo
Journal:  J Gastrointest Surg       Date:  2012-07-03       Impact factor: 3.452

4.  Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Authors:  Michael C Heinrich; Kouros Owzar; Christopher L Corless; Donna Hollis; Ernest C Borden; Christopher D M Fletcher; Christopher W Ryan; Margaret von Mehren; Charles D Blanke; Cathryn Rankin; Robert S Benjamin; Vivien H Bramwell; George D Demetri; Monica M Bertagnolli; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

5.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

6.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authors:  Charles D Blanke; George D Demetri; Margaret von Mehren; Michael C Heinrich; Burton Eisenberg; Jonathan A Fletcher; Christopher L Corless; Christopher D M Fletcher; Peter J Roberts; Daniela Heinz; Elisabeth Wehre; Zariana Nikolova; Heikki Joensuu
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

8.  Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authors:  Ronald P Dematteo; Michael C Heinrich; Wa'el M El-Rifai; George Demetri
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authors:  George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra L Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher Corless; Christopher D M Fletcher; Heikki Joensuu
Journal:  N Engl J Med       Date:  2002-08-15       Impact factor: 91.245

10.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728
View more
  1 in total

1.  Synchronous, Yet Genomically Distinct, GIST Offer New Insights Into Precise Targeting of Tumor Driver Mutations.

Authors:  Eleftherios A Makris; Ashwyn K Sharma; Erik N Bergstrom; Xiaojun Xu; Jorge de la Torre; Sudeep Banerjee; Vi Nguyen; Mojgan Hosseini; Adam Burgoyne; Olivier Harismendy; Ludmil B Alexandrov; Jason K Sicklick
Journal:  JCO Precis Oncol       Date:  2021-03-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.